Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile7 entries
2021
Humana sues Regeneron over alleged Eylea pricing scheme
Lawsuit filed
Humana filed suit against Regeneron, alleging that Regeneron and the Chronic Disease Foundation engaged in a scheme involving Eylea that defrauded Medicare and its contracted payors. The complaint alleged that Regeneron inflated Eylea's price and provided illegal kickbacks to the foundation; these are allegations, not a stated court finding.
Source excerpt
Humana Inc. filed suit against Regeneron Pharmaceuticals, Inc. Thursday in the Southern District of New York over allegations that the pharmaceutical company engaged in a scheme with the Chronic Disease Foundation. The plaintiff claims that as a result of this purported scheme, which they believe is a “sham charity,” the two parties defrauded Medicare and its contracted payors out of hundreds of millions of dollars.
The plaintiff said that Regeneron inflated the price of Eylea and then provided illegal kickbacks to the CDF, which then used the tainted donations they received from Regeneron to cover cost-sharing obligations for patients so that they would continue to choose Eylea rather than its less expensive alternatives.
2021
Class-action suit filed against Humana and Cotiviti over data breach
Lawsuit filed
Steven K. Farmer filed a suit against Humana and Cotiviti alleging that the companies failed to safeguard personal and health information, which was exposed in a data breach. The suit was later removed to federal court.
Source excerpt
The suit was originally filed in May but was removed to federal court Thursday.
Steven K. Farmer is bringing suit against Humana, Inc., and Coviti, Inc. over claims that the companies failed to “properly secure and safeguard personal and sensitive information,” which ultimately led to a data breach that compromised Farmer and other class members’ personal identifying information (PII) and personal health information (PHI).
The plaintiff asserted that Cotiviti shared both the PII and PHI with a subcontractor who disclosed the information to “unauthorized individuals to promote a personal business endeavor.”
2019
Generic-drug price-fixing lawsuit
Humana filed litigation alleging that dozens of defendants participated in a far-reaching conspiracy to fix prices for generic drugs.
2019
Humana sues pharmaceutical companies over generic drug prices
Lawsuit filed
Humana filed a lawsuit alleging that 37 pharmaceutical companies engaged in an industrywide conspiracy that caused prices of several generic drugs to rise. The allegation is the plaintiff's claim, not a court determination.
Source excerpt
Louisville-based Humana Inc. has filed a 600-plus page lawsuit alleging 37 pharmaceutical companies — several of which are international powerhouses — engaged in an industrywide conspiracy that sent the cost of several generic drugs skyrocketing.
Filed on Friday, the lawsuit from the Louisville-based health insurer and health services provider claims the so-called conspiracy resulted in some generic drug prices increasing by over 1,000 percent.
2009
Investigation into Medicare mailings
The U.S. Department of Health and Human Services investigated Humana mailings to Medicare recipients that critics said could be mistaken for official government information and contained claims about healthcare reform. Regulators instructed the company to suspend the mailings while the matter was reviewed.
1999
Dispute over coverage of transplant treatment
A television program produced by Michael Moore criticized Humana over the denial of treatment for a diabetic patient requiring a transplant. Following the public action, Humana changed its policy and authorized treatment, while later disputing aspects of the account.
1996
Congressional testimony on managed-care incentives
Physician Linda Peeno, who had worked as a Humana contractor, testified before Congress about managed-care incentives and alleged that a coverage decision had been financially rewarded. Humana later disputed her characterization and employment status.